CAMBRIDGE, Mass., June 22, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced that it is expanding its clinical development program for IPI-926, a novel, oral small ...
Encouraging Topline Data From Phase 1 Study of IPI-940 Reported Subscribe to read this story ad-free Get unlimited access to ad-free articles and exclusive content. Decision Demonstrates Strength of ...
Ongoing alliance focuses on cancer and inflammatory diseases. Mundipharma International will put over $50 million into the continued development of partner Infinity Pharmaceuticals’ Phase I-stage oral ...
SAN FRANCISCO--(BUSINESS WIRE)--AppOmni, the leading provider of SaaS security, continues to expand its channel presence with new availability to partners in Australia and New Zealand. This move into ...
INFINITY by Eightco is the secure, global authentication and trust layer that enterprises rely on, verifying human identity at scale The Company is supported by a select group of strategic and ...
SAN JOSE, Calif.--(BUSINESS WIRE)--Stellar Cyber, the cybersecurity illumination company behind the industry’s leading human-augmented autonomous SOC platform, has been honored by CRN ®, a brand of ...
Technical information in this news release has been reviewed and approved by Case Lewis, P.Geo., a "Qualified Person" as defined under NI 43-101 Standards of Disclosure for Mineral Projects and a ...
Infinity Visual and Performing Arts’ INSTILL Program opens doors to Infinity students that can truly change the trajectory of their lives. Group classes and mentorship support combined, hands-on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results